Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    GLP-1 and Weight-Loss Drugs May Curb Alcohol Cravings, Study Finds

    May 14, 2025

    Breaking Barriers: Shelly Castle’s Story of Empowerment and Success

    May 9, 2025

    Adeption offers 50 scholarships for adaptive leadership program

    May 2, 2025
    Facebook X (Twitter) Instagram LinkedIn
    • About Us
    • Press Release
    Saturday, May 17
    Facebook X (Twitter) LinkedIn Instagram
    Business Leaders Review: Best Business Magazine and News OnlineBusiness Leaders Review: Best Business Magazine and News Online
    • Magazines
    • Featured Leaders
    • Technology
      • Big Data
      • Artificial Intelligence
      • Robotics
      • Cloud
      • Cyber Security
      • Storage
      • IoT
      • Blockchain
      • Data Analytics
    • Industry
      • Banking & Finance
      • Construction
      • Digital Marketing
      • Economy
      • Education
      • EV Industry
      • Food & Beverage
      • Healthcare
      • Legal
      • Manufacturing
      • Mining & Metals
      • Pharmaceutical
    • Testimonials
    • Latest News
    • Blogs
    • Awards
    • Contact Us
    Business Leaders Review: Best Business Magazine and News OnlineBusiness Leaders Review: Best Business Magazine and News Online
    Home » Research agreement on CAR-T cancer treatment development concluded between National Cancer Center and Asahi Kasei
    Press Release

    Research agreement on CAR-T cancer treatment development concluded between National Cancer Center and Asahi Kasei

    By NikhilSeptember 28, 2023
    CAR-T cancer treatment

    The National Cancer Center (President: Hitoshi Nakagama, “NCC”) and Asahi Kasei Corp. (President: Koshiro Kudo, “Asahi Kasei”) have signed a joint research agreement to develop cellular immunotherapies utilizing the chimeric antigen receptor T cell (CAR-T cell1) format. This alliance will drive CAR-T cell pipelines established at National Cancer Center Research Institute (Director: Hiroyuki Mano) Division of Cancer Immunology (Chief: Hiroyoshi Nishikawa) towards clinical implementation targeting patients having T cell malignancies with unfavorable prognoses, and those having solid tumors that are resistant against standard immunotherapies.

    NCC currently has three preclinical CAR-T cell pipelines to T cell malignances or solid tumors with definitive proof of concept data, one of which is under preparation for a first-in-human clinical trial. NCC has established procedures of vector production T cell expansion and analytical methods for the CAR-T cells. NCC will transfer its techniques to Asahi Kasei, which will work to establish the process of GMP/GCTP2 CAR-T cell production/qualification for clinical trials, and to further advance development for CDMO3 production in the future commercial phase. As a longer-term goal, the Asahi Kasei–NCC alliance aims to become a global hub for research, development, GMP/GCTP production, and supply of cellar therapy products.

    The Asahi Kasei Group has a proven track record in the development and marketing of biopharmaceutical products, as well as manufacturing technologies for regenerative medicine products. Asahi Kasei will promote this joint research with NCC by leveraging its knowledge and experience, and contribute to the establishment of manufacturing technology for the practical application of CAR-T cell therapy.

    • CAR-T cell (chimeric antigen receptor T cell). A T cell that is genetically modified to express CAR to redirect T cells to and attack tumors. Several types of CAR-T cell products are approved for B cell malignancies such as malignant lymphoma, acute lymphoblastic leukemia, and myeloma.
    • GMP/GCTP (Good Manufacturing Practice/Good Gene, Cellular, and Tissue-based Products Manufacturing Practice). GMP/GCTP is a system for ensuring that products are consistently produced and controlled according to quality standards. Either investigational or commercialized CAR-T cell process must be produced and supplied under the GMP/GCTP condition.
    • CDMO (Contract Development and Manufacturing Organization). A company or institute that supplies services in drug development and manufacturing for pharmaceutical companies including cell manufacturing and qualification of the drug.

    Read more such Press Releases here!

    Cancer Treatmeant CAR-T Cell Research Agreement.

    Related Posts

    Breaking Barriers: Shelly Castle’s Story of Empowerment and Success

    May 9, 2025

    Adeption offers 50 scholarships for adaptive leadership program

    May 2, 2025

    KBP to Contest Injunction Obtained by Novo Nordisk

    March 3, 2025

    Fcode Labs to Release Pioneering Whitepaper on the Power of AI in Delivering Exceptional Customer Experiences

    February 14, 2025

    Microsoft Dynamics 365: The Undisputed Leader in Gartner’s Magic Quadrant

    January 20, 2025

    Localis 365: the solution that makes tax management simpler in Latin America

    December 13, 2024
    Top Posts

    GLP-1 and Weight-Loss Drugs May Curb Alcohol Cravings, Study Finds

    May 14, 2025

    RAGEN & StarPO Aim to Tame LLM Instability in Complex Tasks

    April 25, 2025

    Storage Vendors Compete for AI Dominance at Nvidia GTC 2025

    April 3, 2025
    Don't Miss

    GLP-1 and Weight-Loss Drugs May Curb Alcohol Cravings, Study Finds

    May 14, 2025

    Key Highlights New research suggests that popular weight-loss drugs like Ozempic (semaglutide) and Wegovy may…

    Breaking Barriers: Shelly Castle’s Story of Empowerment and Success

    May 9, 2025

    Adeption offers 50 scholarships for adaptive leadership program

    May 2, 2025

    RAGEN & StarPO Aim to Tame LLM Instability in Complex Tasks

    April 25, 2025
    Stay In Touch
    • Facebook
    • Twitter
    • Instagram
    • LinkedIn
    About Us
    About Us

    Business Leaders Review is a global print and digital monthly and yearly magazine, which provides a platform to showcase business/tech leaders and their company’s profile from various sectors. Our aim is to publish the c-suite leaders stories.

    We are helping the leaders & readers to showcase their ideas and innovations to the business and tech world in this current market situation along with their awards and achievements. Doing so we hope to leverage thousands of businesses and personnel around the globe.

    Most Popular

    Breaking Barriers: Shelly Castle’s Story of Empowerment and Success

    Adeption offers 50 scholarships for adaptive leadership program

    KBP to Contest Injunction Obtained by Novo Nordisk

    Our Picks

    GLP-1 and Weight-Loss Drugs May Curb Alcohol Cravings, Study Finds

    RAGEN & StarPO Aim to Tame LLM Instability in Complex Tasks

    Storage Vendors Compete for AI Dominance at Nvidia GTC 2025

    Facebook X (Twitter) LinkedIn Instagram
    • Home
    • Our Clients
    • Technology
    • Industry News
    • Contact Us
    • Privacy Policy
    • Reprints and Permissions
    © 2025 Business Leaders Review LLC | All Rights Reserved | Empowering Communication Globally

    Type above and press Enter to search. Press Esc to cancel.